Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
753
¥ million (year-on-year decrease in operating profit)Wording
Definitive
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20273 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥17,384 million-1.5%
Operating profit¥711 million-51.4%
Ordinary income¥817 million-48.7%
Net income¥533 million -57.5%profit attributable to owners of the parent
Selling, general and administrative expenses¥73 hundred million up 1.8 percentage points year on year
Results for the three months of the current quarter
Net Sales
¥17,384 million
Operating profit
¥711 million
Ordinary income
¥817 million
Profit attributable to owners of parent for the quarter
¥533 million
Full-year earnings forecast
Net Sales
¥730 100 million+2.6%
Operating profit
¥62 100 million+6.3%
What the company explained in this material
New initiatives
- Conduct of a Phase III study of AKP-022 (relugolix combination drug) for uterine fibroids and endometriosis
- Conduct of a Phase I/II study of LPRI-CF113 (drospirenone) for dysmenorrhea
- Conduct of a specified clinical research study of AKP-SMD106 (digital therapeutics app)
- Conduct of a confirmatory clinical trial of MCN-009 (digital therapeutics app) for irritable bowel syndrome
- Joint development with SUSMED,Inc.
- Joint development with 株式会社MICIN
Key KPIsA metric the company considers important as a management benchmark.
- Ratio of sales from branded products41.2 %Year on year against the same period last yearUp 2.5 percentage points
- Share of sales from generic drugs58.8 %
- Research and development costs¥2,582 million
- Sales of the major product Slinda¥241 millionYear on year against the same period last year+224.9%
- Sales of the major product leuprorelin¥1,064 millionYear on year against the same period last year+10.5%
Segment results
- Prescription Pharmaceutical BusinessSales¥14,484 million (YoY -0.2%)Profit/Loss¥1,132 million (YoY -33.3%)
- Animal Health BusinessSales¥1,952 million (YoY +6.1%)Profit/Loss¥44 million (YoY -65.4%)
- Overseas BusinessSales¥908 million (YoY -25.9%)Profit/Loss¥-35 million
- Other businesses (clinical testing, medical devices, etc.)Sales¥38 million (YoY -33.4%)Profit/Loss¥-8 million
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥17,384 million (YoY -1.5%) |
| Operating profit | ¥711 million (YoY -51.4%) |
| Ordinary income | ¥817 million (YoY -48.7%) |
| Net income | ¥533 million (profit attributable to owners of the parent) (YoY -57.5%) |
| Selling, general and administrative expenses | ¥73 hundred million (up 1.8 percentage points year on year) |
| Results for the three months of the current quarter | Net Sales ¥17,384 million / Operating profit ¥711 million / Ordinary income ¥817 million / Profit attributable to owners of parent for the quarter ¥533 million |
| Full-year earnings forecast | Net Sales ¥730 100 million (YoY +2.6%) / Operating profit ¥62 100 million (YoY +6.3%) / Ordinary income Not disclosed / Net income Not disclosed |
| Segment results | Segment Prescription Pharmaceutical Business / Sales ¥14,484 million (YoY -0.2%) / Profit/Loss ¥1,132 million (YoY -33.3%), Segment Animal Health Business / Sales ¥1,952 million (YoY +6.1%) / Profit/Loss ¥44 million (YoY -65.4%), Segment Overseas Business / Sales ¥908 million (YoY -25.9%) / Profit/Loss ¥-35 million, Segment Other businesses (clinical testing, medical devices, etc.) / Sales ¥38 million (YoY -33.4%) / Profit/Loss ¥-8 million |
| Key KPIs | Indicator name Ratio of sales from branded products / Value 41.2 % / Year on year against the same period last year Up 2.5 percentage points, Indicator name Share of sales from generic drugs / Value 58.8 % / Year on year against the same period last year Not disclosed, Indicator name Research and development costs / Value ¥2,582 million / Year on year against the same period last year Not disclosed, Indicator name Sales of the major product Slinda / Value ¥241 million / Year on year against the same period last year ¥224.9 million, Indicator name Sales of the major product leuprorelin / Value ¥1,064 million / Year on year against the same period last year ¥10.5 million |
| New initiatives | Conduct of a Phase III study of AKP-022 (relugolix combination drug) for uterine fibroids and endometriosis, Conduct of a Phase I/II study of LPRI-CF113 (drospirenone) for dysmenorrhea, Conduct of a specified clinical research study of AKP-SMD106 (digital therapeutics app), Conduct of a confirmatory clinical trial of MCN-009 (digital therapeutics app) for irritable bowel syndrome, Joint development with SUSMED,Inc., Joint development with 株式会社MICIN |
Items this document does not state (19)
Gross Profit MarginOperating profit marginProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The prescription pharmaceuticals business was affected by ongoing NHI drug price revisions, while the overseas business experienced difficulties procuring the active pharmaceutical ingredients for its core products amid worsening conditions in the Middle East. On the earnings front, the increase in cost of sales resulting from higher raw material prices and other factors, as well as higher research and development expenses associated with progress in clinical trials, contributed to the decline in profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.